文献速递免疫规划卫生政策与健康促进

含麻疹成分疫苗不同开瓶阈值的经济影响建模

Modeling the economic impact of different vial-opening thresholds for measles-containing vaccines.
PubMed 文献 · Vaccine · 2019-03-23

研究利用HERMES模拟模型评估贝宁、莫桑比克和尼日尔常规免疫供应链中不同开瓶阈值(无、30%、60%)和MCV规格(10剂、5剂)的影响,并链接临床与经济结局模型。结果显示最优阈值因国家而异,但10剂MCV采用30%开瓶阈值在三国均能改善疫苗可得性并减少医疗成本和DALYs。

要点

  • 10剂MCV采用30%开瓶阈值在贝宁、莫桑比克和尼日尔均较无阈值基线一致获益。
  • 贝宁(中位接种场次规模5)下30%阈值并匹配10剂/5剂分布最具成本效果,避免671 DALYs($471/DALY averted)。
  • 尼日尔(中位场次规模9)下60%阈值并匹配规格最具成本效果,避免2897 DALYs($16.05/DALY averted)。

核心结论

  • MCV理想开瓶阈值因供应链而异,但10剂MCV采用30%开瓶阈值在贝宁、莫桑比克和尼日尔均较无阈值基线一致改善疫苗可得性并降低相关医疗成本和DALYs。

研究设计与样本

  • 使用HERMES生成的贝宁、莫桑比克和尼日尔常规免疫供应链模拟模型,评估开瓶阈值(无、30%、60%)和MCV规格(10剂、5剂)的影响。
  • 将供应链输出链接至临床与经济结局模型,将疫苗可得性变化转化为感染、医疗成本和DALYs,并从卫生系统视角计算经济影响。

主要发现

  • 贝宁(中位接种场次规模=5)实施30%开瓶阈值并按场次规模匹配10剂和5剂MCV分布最具成本效果,较基线(无阈值、10剂MCV)避免671 DALYs($471/DALY averted)。
  • 尼日尔(中位MCV场次规模=9)设置60%开瓶阈值并匹配MCV规格最具成本效果,避免2897 DALYs($16.05/DALY averted)。
  • 莫桑比克(中位场次规模=3)使用10剂MCV设置30%开瓶阈值是较基线唯一有益的政策,避免3081 DALYs($85.98/DALY averted)。
  • 三国中,10剂MCV统一采用30%开瓶阈值是唯一较基线一致惠及每个系统的MCV阈值。

关键数值与推荐

  • 贝宁:30%开瓶阈值并匹配10剂/5剂分布,较基线避免671 DALYs($471/DALY averted)。
  • 尼日尔:60%开瓶阈值并匹配MCV规格,较基线避免2897 DALYs($16.05/DALY averted)。
  • 莫桑比克:10剂MCV采用30%开瓶阈值,较基线避免3081 DALYs($85.98/DALY averted)。

临床怎么用

  • 在10剂MCV接种场景中,可优先考虑实施30%开瓶阈值以改善疫苗可得性并减少医疗成本和DALYs。
  • 开瓶阈值政策应结合各国接种场次规模等供应链特征进行本地化选择,并匹配相应MCV规格。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The lack of specific policies on how many children must be present at a vaccinating location before a healthcare worker can open a measles-containing vaccine (MCV) - i.e. the vial-opening threshold - has led to inconsistent practices, which can have wide-ranging systems effects. METHODS: Using HERMES-generated simulation models of the routine immunization supply chains of Benin, Mozambique and Niger, we evaluated the impact of different vial-opening thresholds (none, 30% of doses must be used, 60%) and MCV presentations (10-dose, 5-dose) on each supply chain. We linked these outputs to a clinical- and economic-outcomes model which translated the change in vaccine availability to associated infections, medical costs, and DALYs. We calculated the economic impact of each policy from the health system perspective. RESULTS: The vial-opening threshold that maximizes vaccine availability while minimizing costs varies between individual countries. In Benin (median session size = 5), implementing a 30% vial-opening threshold and tailoring distribution of 10-dose and 5-dose MCVs to clinics based on session size is the most cost-effective policy, preventing 671 DALYs ($471/DALY averted) compared to baseline (no threshold, 10-dose MCVs). In Niger (median MCV session size = 9), setting a 60% vial-opening threshold and tailoring MCV presentations is the most cost-effective policy, preventing 2897 DALYs ($16.05/ DALY averted). In Mozambique (median session size = 3), setting a 30% vial-opening threshold using 10-dose MCVs is the only beneficial policy compared to baseline, preventing 3081 DALYs ($85.98/DALY averted). Across all three countries, however, a 30% vial-opening threshold using 10-dose MCVs everywhere is the only MCV threshold that consistently benefits each system compared to baseline. CONCLUSION: While the ideal vial-opening threshold policy for MCV varies by supply chain, implementing a 30% vial-opening threshold for 10-dose MCVs benefits each system by improving overall vaccine availability and reducing associated medical costs and DALYs compared to no threshold.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wedlock PT, Mitgang EA, Oron AP, et al. Modeling the economic impact of different vial-opening thresholds for measles-containing vaccines. Vaccine. 2019. PMID: 30914223. doi:10.1016/j.vaccine.2019.03.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。